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Percutaneous repair of sinus venosus defect with anomalous pulmonary
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Wereport thefirst-in-mancombinedpercutaneous
repair of a sinus venosus atrial septal defect
(SVASD) with anomalous pulmonary venous
return (APVR).
A 65-year-old woman with increasing exertional
dyspnoea was diagnosed by cardiac echocardiog-
raphy with a 12 × 8 mm SVASD and APVR of the
right upper pulmonary vein (RUPV) into the
lateral wall of the superior vena cava (SVC).
Qp:Qs was 2.7:1. The patient refused open heart
surgery.
The interventionwas done under local anaesthe-
sia and fluoroscopic guidance. A regular 0.035′′
guidewire, a 6 French (F) multipurpose catheter,
and a 9 F TorqVue sheath (St Jude, Plymouth, MN,
USA) were used to implant a 15 mm Amplatzer
atrial septal defect (ASD) occluder (St Jude) into
the SVASD, gauged at 8 × 9 mm with a 24 mm
Amplatzer sizing balloon (St Jude) [Panel A, left:
postero-anterior (PA), right: lateral (Lat) view]. The anomalous RUPVwas documentedwith pulmonary (Panel B; top) and direct dye injec-
tions during temporary occlusion using the 24 mm sizing balloon (Panel B; bottom). There were no symptoms and wash-out of the dye
through collaterals was prompt. The anomalous RUPV was plugged with an 18 mm Amplatzer ventricular septal defect occluder of
which the distal disk remained constrained like a blimp (Panel C). The patient was discharged on clopidogrel for 1month and acetylsalicylic
acid for 2 months the next day after transthoracic echocardiography and chest X-ray (Panel D). Dyspnoea disappeared immediately and
transoesophageal echocardiography at 2 months showed no residual shunt at rest. Medical therapy was stopped.
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